Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Ginsenoside Rg1

Catalog No: tcsc3832

Available Sizes

Size: 5mg

Size: 10mg

Specifications

CAS No:
22427-39-0

Formula:
$C_{42}H_{72}O_{14}$

Pathway:
Neuronal Signaling;NF-κB

Target:
Amyloid-β;NF-κB

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 8.1 mg/mL (10.11 mM)

Alternative Names:
Panaxoside A;Panaxoside Rg1

Observed Molecular Weight:
801.01

Product Description

Ginsenoside Rg1 is one of the major active components of ginseng. Ginsenoside Rg1 displays promising effects by reducing cerebral **Aβ** levels. Ginsenoside Rg1 also reduces **NF-κB** nuclear translocation.

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

IC50 & Target: Aβ[1]

NF-κB p65[2]

In Vitro: Ginsenoside Rg1 promotes the proliferation and differentiation of human dental pulp cells (hDPCs). The proliferative ability of hDPCs in Ginsenoside Rg1 is significantly enhanced (p[3]. In the RAW264.7 cells stimulated by lipopolysaccharides (LPS) , the level of p-IκBα and p-p65 is significantly higher than in controls and PPAR-γ levels are significantly lower. Treatment with Rg1 vitro inhibits IκBα phosphorylation, reduces NF-κB nuclear translocation and upregulates PPAR-γ expression[2].

In Vivo: In the inflamed joints of adjuvant-induced arthritis (AIA) rats, the level of p-IκBα and p-p65 is significantly higher than in controls and PPAR-γ levels are significantly lower. Treatment with Ginsenoside Rg1 in vivo inhibits IκBα phosphorylation, reduces NF-κB nuclear translocation and upregulates PPAR-γ expression[2]. Ginsenoside Rg1 (G-Rg1) and Ginsenoside Rg2 (G-Rg2) reduce the escape latencies on the last two training days compared to the Alzheimer\'s disease (AD) model group (p1-42 accumulation in APP/PS1 mice. In the Ginsenoside Rg1 and Ginsenoside Rg2 treated mice, the pathological abnormalities observed in the APP/PS1 mice are gradually ameliorated. Clear nucleoli and light brown, sparsely scattered Aβ deposits are visible[1].